Bezwoda W R, Derman D P, Bothwell T H, MacPhail A P, Torrance J D, Milne F J, Meyers A M, Levin J
Nephron. 1981;28(6):289-93. doi: 10.1159/000182220.
Various haematological, ferrokinetic and iron absorption measurements were carried out on 15 patients with chronic renal failure who were undergoing regular haemodialysis. There was no evidence that the rate of iron absorption was impaired significantly by the depressed erythropoietic activity present in these patients. In contrast, there was a significant inverse correlation between the rate of iron absorption and the serum ferritin concentration, which has been shown to be an index of the size of the iron stores. This relationship, which was shown with both small (3 mg) and large (50 mg) doses of ferrous iron, was no different from that previously noted in subjects with normal renal function. These results suggest that iron deficiency in patients with chronic renal failure undergoing regular haemodialysis can be adequately prevented or treated with oral iron therapy, since the absorptive mechanism for iron appears to be normal.
对15例接受定期血液透析的慢性肾衰竭患者进行了各种血液学、铁动力学和铁吸收测量。没有证据表明这些患者存在的红细胞生成活性降低会显著损害铁吸收速率。相反，铁吸收速率与血清铁蛋白浓度之间存在显著负相关，血清铁蛋白浓度已被证明是铁储存量的指标。这种关系在小剂量（3毫克）和大剂量（50毫克）的亚铁中均有体现，与之前在肾功能正常的受试者中观察到的情况没有差异。这些结果表明，接受定期血液透析的慢性肾衰竭患者的缺铁情况可以通过口服铁剂治疗得到充分预防或治疗，因为铁的吸收机制似乎是正常的。
